Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TARS1 | P26639 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | PRF1 | P14222 | 4/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15730875 | 0.83 | CLK4 (0.58) | PRKCICLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL24680750 | 0.81 | PRKCI (0.52) | PRKCICLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL18853930 | 0.80 | PRKCI (0.49) | PRKCICLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL34460942 | 0.79 | GRM2 (0.45) | PRKCICLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL15708952 | 0.78 | GSK3B (0.41) | PRKCICLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL14484397 | 0.78 | GSK3B (0.41) | PRKCICLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL15723973 | 0.76 | UGCG (0.47) | GRM5PRF1 | |
| SCHEMBL23501971 | 0.76 | GRIA1 (0.60) | TGFBR1ACVR1 | |
| SCHEMBL15980671 | 0.75 | GSK3B (0.51) | PRKCICLK4GSK3BDAPK3NTRK1 | |
| SCHEMBL16154663 | 0.75 | CLK4 (0.54) | PRKCICLK4GSK3BDAPK3NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | PRKCI 3386/4885CLK4 4388/4885GSK3B 1733/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | PRKCI 3386/4885CLK4 4388/4885GSK3B 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.